Evofem Biosciences (EVFM) Competitors $0.0094 0.00 (-4.08%) (As of 12/20/2024 05:18 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends EVFM vs. OGEN, CELZ, APM, SNPX, HEPA, INM, PTIX, CHRO, SNOA, and ATXIShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Oragenics (OGEN), Creative Medical Technology (CELZ), Aptorum Group (APM), Synaptogenix (SNPX), Hepion Pharmaceuticals (HEPA), InMed Pharmaceuticals (INM), Protagenic Therapeutics (PTIX), Chromocell Therapeutics (CHRO), Sonoma Pharmaceuticals (SNOA), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Oragenics Creative Medical Technology Aptorum Group Synaptogenix Hepion Pharmaceuticals InMed Pharmaceuticals Protagenic Therapeutics Chromocell Therapeutics Sonoma Pharmaceuticals Avenue Therapeutics Oragenics (NYSE:OGEN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends. Does the media favor OGEN or EVFM? In the previous week, Oragenics had 3 more articles in the media than Evofem Biosciences. MarketBeat recorded 3 mentions for Oragenics and 0 mentions for Evofem Biosciences. Oragenics' average media sentiment score of 0.25 beat Evofem Biosciences' score of 0.00 indicating that Oragenics is being referred to more favorably in the media. Company Overall Sentiment Oragenics Neutral Evofem Biosciences Neutral Do institutionals & insiders hold more shares of OGEN or EVFM? 18.7% of Oragenics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 10.1% of Oragenics shares are owned by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, OGEN or EVFM? Evofem Biosciences has higher revenue and earnings than Oragenics. Oragenics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K108.45-$20.66M-$7.07-0.05Evofem Biosciences$11.39M0.09$52.98M-$0.62-0.02 Is OGEN or EVFM more profitable? Oragenics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% Evofem Biosciences -46.42%-91.97%-61.93% Which has more risk & volatility, OGEN or EVFM? Oragenics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.87, meaning that its share price is 187% less volatile than the S&P 500. Does the MarketBeat Community believe in OGEN or EVFM? Evofem Biosciences received 262 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes37100.00% Evofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% SummaryEvofem Biosciences beats Oragenics on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0210.5990.1317.19Price / Sales0.09196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.005.094.784.78Net Income$52.98M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem BiosciencesN/A$0.01-4.1%N/A-83.9%$1.07M$11.39M-0.02120Gap UpOGENOragenicsN/A$0.34+3.0%N/AN/A$4.15M$40,000.000.005Analyst ForecastNews CoverageGap UpCELZCreative Medical Technology0.5925 of 5 stars$2.34+6.8%N/A-55.2%$4.10M$10,000.00-0.615Positive NewsAPMAptorum Group0.3987 of 5 stars$0.76-1.2%N/A-66.2%$3.93M$431,378.000.0030News CoverageGap DownSNPXSynaptogenix1.3915 of 5 stars$2.80+4.1%$14.00+400.0%-54.5%$3.81MN/A0.004News CoverageHEPAHepion PharmaceuticalsN/A$0.54-7.9%N/A-84.4%$3.78MN/A-0.1320INMInMed Pharmaceuticals0.4358 of 5 stars$5.23-0.6%N/A-36.5%$3.76M$4.96M-0.3813News CoveragePositive NewsGap DownPTIXProtagenic Therapeutics0.8347 of 5 stars$0.54+9.1%N/A-27.7%$3.67MN/A-0.391Positive NewsGap UpCHROChromocell TherapeuticsN/A$0.60+2.5%N/AN/A$3.62MN/A0.004SNOASonoma Pharmaceuticals0.5922 of 5 stars$2.69+0.7%N/A+1,608.9%$3.61M$12.73M0.00180ATXIAvenue Therapeutics2.1972 of 5 stars$1.75-2.8%N/A-83.3%$3.59MN/A0.104 Related Companies and Tools Related Companies Oragenics Alternatives Creative Medical Technology Alternatives Aptorum Group Alternatives Synaptogenix Alternatives Hepion Pharmaceuticals Alternatives InMed Pharmaceuticals Alternatives Protagenic Therapeutics Alternatives Chromocell Therapeutics Alternatives Sonoma Pharmaceuticals Alternatives Avenue Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVFM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
